Information
SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET to provide
Original sourceAI Summary
Crinetics Pharmaceuticals is set to provide an update on the commercialization of PALSONIFY and share topline results from its atumelnant clinical trial on January 5, 2026. This announcement is particularly significant for investors looking for insights into new developments within the company’s promising pipeline.
Trading Thesis
Expect potential stock movement based on clinical trial results and commercialization strategy.
Market-Moving
- PALSONIFY updates could influence investor sentiment positively.
- Atumelnant trial results may indicate future growth trajectories.
- Investors will closely watch the Q&A for strategic insights.
- News could sway analysts' ratings on CRNX.
- An optimistic outlook from the call may boost stock momentum.
Key Facts
- Crinetics hosts a conference call on January 5, 2026.
- PALSONIFY is FDA-approved for acromegaly treatment.
- Atumelnant targets congenital adrenal hyperplasia.
- Crinetics has over ten developmental programs.
- The call will feature a live question-and-answer session.
Companies Mentioned
- Crinetics Pharmaceuticals (CRNX): Updates on PALSONIFY and clinical trials directly impact CRNX stock.
Corporate Developments
The developments surrounding Crinetics present significant opportunities within the endocrine disease treatment space. The ongoing trials and FDA approvals contribute to the broader market's interest in innovative therapies.
FAQ
Why Bullish?
Positive updates on PALSONIFY and atumelnant could result in increased investor confidence, similar to past FDA approvals that have led to stock rallies in biotech firms.
How important is it?
The results from the Phase 2 trial and PALSONIFY updates are critical for CRNX, potentially attracting investor attention and moving the stock price.
Why Short Term?
The upcoming conference call and trial results are expected to quickly influence CRNX stock performance, reminiscent of other biotech firms that experienced immediate stock price fluctuations after pivotal announcements.
SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET to provide an update on PALSONIFY™ (paltusotine) commercialization and disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia.
Conference Call and Webcast Details
Management will hold a live conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET. A live question-and-answer session will follow the prepared remarks. To access the live audio-only webcast, click here. The archived webcast will also be accessible on the Events & Presentations page in the Investors section of the Crinetics' website at www.crinetics.com/events. To participate, please dial 1-833-470-1428 (domestic) or 1-646-844-6383 (international) and refer to Access Code 640078.
ABOUT CRINETICS PHARMACEUTICALS
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.
Crinetics' lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics' deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, and CRN09682, a nonpeptide drug conjugate candidate that is being developed to treat SST2 expressing neuroendocrine tumors and other SST2 expressing solid tumors. Additional discovery programs address a variety of endocrine conditions such as neuroendocrine tumors, Graves' disease (including Graves' hyperthyroidism and Graves' orbitopathy, or thyroid eye disease), polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075
